The researchers discovered that 10.6% of exposed household contacts developed symptomatic illness within 14 days of exposure to asymptomatic test-positive children, a rate higher than expected.
The Food and Drug Administration (FDA) on March 22 granted emergency use authorization (EUA) for Invivyd's monoclonal antibody to prevent COVID-19 in immunocompromised patients, which fills a gap following the withdrawal of Evusheld in January 2023.
